Hook & thesis
Hims & Hers (HIMS) is offering an actionable entry after a messy quarter. The stock is trading near $24 after a post-earnings swoon driven by margin compression and a swing to GAAP losses; that reaction overshoots the underlying opportunity. The company still grew revenue to $608.1 million in Q1 and raised full-year revenue guidance to $2.8 - $3.0 billion, and the newly secured ability to sell branded GLP-1 therapies gives it a fast, high-volume product to commercialize through its direct-to-consumer platform.
My read: this is a tactical long. The market punished HIMS for margin hits tied to a strategic pivot and heavier investment in international expansion, AI and diagnostics. Those are sensible growth moves. If you agree management can re-compress margins over time while scaling branded drug sales, the current price offers attractive asymmetric upside versus the downside from a measured stop-loss.
What the company does and why the market should care
Hims & Hers operates a telehealth platform that connects consumers to healthcare professionals across mental health, sexual health, dermatology and primary care. Over the last 18 months the company has repositioned its pharmacy business by making a high-profile deal that allows it to sell branded GLP-1 products such as Wegovy through its platform. That pivot turns HIMS from primarily a compounding/reseller model toward moving high-volume branded drugs - a meaningful re-rating vector if they can capture share in the booming weight-loss category.
Why the market cares: branded GLP-1s are high-demand, recurring prescriptions that drive order frequency and higher lifetime value for direct-to-consumer health platforms. Management now guides to $2.8 - $3.0 billion in 2026 revenue and talks about a $6.5 billion revenue runway by 2030, putting the company in a different growth bucket than a pure virtual-care roll-up.
Key numbers that matter
- Q1 revenue: $608.1 million (4% year-over-year growth).
- Q1 net: a $92.1 million loss (swing from prior year profit), with adjusted EBITDA down materially (~51% per commentary).
- 2026 revenue guidance: raised to $2.8 - $3.0 billion.
- Gross margin: compressed from ~73% to ~65% on the GLP-1 pivot and product mix shift.
- Market cap: about $5.51 billion; enterprise value: about $6.36 billion.
- Valuation multiples: price-to-sales ~2.37; EV-to-sales ~2.68; EV/EBITDA ~169 (reflecting near-term EBITDA compression).
- Free cash flow (trailing): ~$66.9 million; EPS (trailing) about -$0.06 per share.
- Shares outstanding: ~227.94 million; float: ~206.3 million.
Why I think the selloff is a buying opportunity
Two dynamics are at play. First, much of the negative reaction is tied to near-term margin compression as HIMS shifts from high-margin compounded products toward branded weight-loss meds sold at lower per-unit gross margin but with much larger addressable volume. That strategy reduces margin in the short run but materially increases TAM and repeat purchase potential. Second, management increased revenue guidance despite the Q1 miss, signaling real demand: they reported fulfilling over 125,000 Wegovy shipments in early partnership activity, which is concrete momentum.
On valuation, you pay about $2.37 in price-to-sales versus a growth profile that can accelerate if branded product sales scale. EV/EBITDA looks punitive at ~169x because EBITDA is depressed by one-time investments and mix shifts. If EBITDA margins normalize toward historical levels as new product categories scale, the multiple can compress dramatically and produce outsized returns.
Technical and market structure notes
HIMS recently traded as low as $13.74 and as high as $70.43 in the last 52 weeks, showing the stock can move sharply on news and sentiment. Current price sits roughly at the 50-day simple moving average ($24.15) which provides a nearby support reference. Momentum indicators are mixed - RSI near 45 and MACD showing bearish momentum - so expect volatility around earnings reactions and GLP-1 headlines. Short interest remains meaningful (tens of millions of shares) and recent trading shows high short volume on big days, which can magnify both dips and rallies.
Trade plan (actionable)
Recommendation: Buy HIMS at $24.00. This is a directional long that assumes the market has over-penalized near-term margin weakness and that branded GLP-1 distribution will add durable revenue and improve unit economics over the next several quarters.
| Entry | Stop | Target | Horizon | Risk/Reward (approx) |
|---|---|---|---|---|
| $24.00 | $19.50 | $36.00 | long term (180 trading days) | ~1:2.8 (downside ~18.8%, upside ~50%) |
Why long term (180 trading days)? The mix shift to branded GLP-1s and the investments in international expansion and diagnostics will take multiple quarters to show margin improvement and scale benefits. I want to give management time to prove execution on drug distribution, cadence of repeat prescriptions, and cost control as the company integrates higher-volume branded pharmaceuticals.
Catalysts to watch (2-5)
- Execution on branded GLP-1 distribution - sustained shipment growth beyond the initial ~125,000 Wegovy shipments will materially de-risk the revenue story.
- Margins and adjusted EBITDA trajectory - signs that gross margin stabilizes and adjusted EBITDA guidance turns up would validate the pivot.
- Subscriber and repeat-purchase metrics - accelerating patient retention or average revenue per user would support higher valuation multiples.
- Regulatory news that broadens access to peptides or improves reimbursement could unlock upside.
- Macro and sector flows - a more constructive tape for growth/healthcare could reduce valuation compression and lift HIMS.
Risks and counterarguments
- Counterargument - structural margin deterioration: The shift to branded weight-loss drugs may be permanent and lower-margin than the legacy compounding business, leaving revenue growth but lower profitability. If margins do not recover, multiples justified by higher profitability may never arrive and the stock could remain range-bound or lower.
- Execution risk: Scaling distribution of regulated, branded drugs at volume requires logistics, pharmacy operations and payer relationships. Any missteps or fulfillment issues could slow adoption and frustrate revenue growth.
- Regulatory and legal risk: Changes in regulation around compounding, telehealth prescribing or GLP-1 distribution could impact product availability and margins.
- Macroeconomic/market risk: With a stretched risk-on environment, HIMS can get further repriced lower if growth stocks sell off broadly; its EV/EBITDA multiple is sensitive to sentiment.
- Balance sheet & leverage: Debt-to-equity sits elevated at ~2.18; while current and quick ratios are above 1, slower cash generation could strain flexibility if investments continue while EBITDA is depressed.
What would change my mind
I would exit or avoid adding if HIMS fails to show sequential improvement in gross margins or adjusted EBITDA over two consecutive quarters, or if branded GLP-1 shipment growth stalls materially below the initial traction (no meaningful increase beyond the early ~125k Wegovy shipments). Conversely, a faster-than-expected recovery in margins or evidence of stronger repeat prescription rates would push me to add size and raise the target.
Bottom line: The headline numbers out of Q1 were ugly enough to spook short-term traders, but the underlying revenue growth, raised 2026 guidance, and a clear path into branded GLP-1 sales create a favourable asymmetric trade. Buy around $24.00 with a $19.50 stop and a $36.00 target over a 180 trading-day horizon, but make this a position you size for volatility and monitor margin signals closely.
Trade idea prepared by Maya Rios at TradeVae.